Date:

N&WICS - TA786 - Tucatinib with trastuzumab and capecitabine - HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies								
Before providing patient identifiable data on this form, please confirm that the patient (or in the case of a minor or vulnerable adult with the parent/legal guardian/carer) has given appropriate explicit consent for sensitive personal information on this form to be passed to the CCG and/or CSU for processing this funding request and validating subsequent invoices. Consent given:								
If there is more than one NICE-approabout the advantages and disadvant patient is likely to adhere to treatme	ages of the treatments availant. The most appropriate, lea	ble. This has taken into cor st expensive, will be chose	nsideration therapeu	tic need and wheth	ner or not the			
and price per dose) unless an order	of preference is stated in the	TAS.	T					
Patient NHS No:	Trust:		Practice Name:					
Patient Hospital No:	Consultant Making Request:		Practice Postcode:					
Patient's Initials and DoB:			Practice Code:					
Notification Email Address:	(@NHS.ne	et account ONLY)	Contact name & number:					
Start date of requested treatment:	Committee	e □NHS care □Hospital	Sub-Type:	/A 🔽				
By completing this form, you confirm that you intend to use the requested medicinal product described below as agreed in the local commissioning statement. Any requests which fall outside of this use will require an individual funding request (IFR). For support regarding IFRs, please contact: norfolkicd@nhs.net For support regarding the criteria listed below, please contact: norfolknontariff@nhs.net								
Please indicate whether patient meets the following NICE criteria:				Please tick				
1. Tucatinib with trastuzumab and capecitabine is recommended, within its marketing authorisation, as an option for treating HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies, only if the company provides tucatinib according to the commercial arrangement.								
As per NICE guidance, treatment should normally be started with the least expensive drug (considering the dose required, price per dose and any additional administration costs). Please confirm that the choice of drug is considered the most cost-effective treatment for this individual patient, noting that alternative treatment options recommended by NICE may be lower in cost, including the use of biosimilar medications if applicable.								
Where an alternative lower cost to that the clinical rationale for presonauditing.								
3. The product is being used as described by local commissioning position.								
I confirm that the patient meets	s the criteria for treatment							
Name of person completing:		Contact Details:						
Designation of person completing: Date:								
Trust Authorising Pharmacist		1						
Nama	1							